How does one ‘define value’ when considering a new technology? How does one create value when building a company on a novel platform? In today’s market, how does one price innovation in different healthcare systems?

Join us for the 12th annual Business of Regenerative Medicine conference, where distinguished speakers will provide insights — as well as guardrails — for navigating the emerging industry of regenerative medicine.

Engage with CEOs, venture capitalists, experts in biomedical research, and patient advocates to explore how advances in cell and gene therapy, drug development, and bioengineering in regenerative medicine are moving from the lab to the patient — and what it will take to identify real, lasting value for business and society.

Speakers include:

Sangeeta Bhatia, Ph.D.
Massachusetts Institute of Technology/Brigham and Women’s Hospital

Mark Fishman, M.D.
Harvard University

George Church, Ph.D.
Harvard Medical School

Geraldine Hamilton, Ph.D.
Emulate, Inc.

George Q. Daley, M.D., Ph.D.
Harvard Medical School

Paula Hammond, Ph.D.
Massachusetts Institute of Technology

Program and registration: https://brm2019.hsci.harvard.edu

The Business of Regenerative Medicine meeting series is organized and managed collaboratively by:
Harvard Stem Cell Institute
National Center for Regenerative Medicine, Case Western Reserve University
CCRM: Commercializing Living Therapies
Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Tech
Institute for Regenerative Medicine, University of Pennsylvania